Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors. The company’s lead product, Polyclonal Antibody Stimulator (PAS), is an immunomodulator that blocks the function of gastrin. This inhibition slows tumor growth, the incidence of metastasis, and also changes the tumor microenvironment.
PAS, An Interview with Lynda Sutton
Advancing Cancer Therapy
Our goal is to improve the quality of life and to extend the survival of patients with gastrointestinal cancers. Currently, Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors and exploring synergy between treatment classes. Our most recent nonclinical research suggests that PAS can be used to increase the efficacy of PD-1 Checkpoint Inhibitors by turning a pancreatic cancer tumor from “cold” to “hot”.
Pioneering new medicines and redefining possibilities for cancer patients.
Cancer Advances
Westpark Corporate Center
4364 South Alston Avenue,
Suite 105 Durham, North Carolina
USA 27713
© 2024 Cancer Advances, Inc. All rights reserved.